Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial.

MLA

Wu, Hong Gyun, et al. “Therapeutic Effect of Recombinant Human Epidermal Growth Factor (RhEGF) on Mucositis in Patients Undergoing Radiotherapy, with or without Chemotherapy, for Head and Neck Cancer: A Double-Blind Placebo-Controlled Prospective Phase 2 Multi-Institutional Clinical Trial.” Cancer, vol. 115, no. 16, Aug. 2009, pp. 3699–708. EBSCOhost, https://doi.org/10.1002/cncr.24414.

APA

Wu, H. G., Song, S. Y., Kim, Y. S., Oh, Y. T., Lee, C. G., Keum, K. C., Ahn, Y. C., & Lee, S. (2009). Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial. Cancer, 115(16), 3699–3708. https://doi.org/10.1002/cncr.24414

Chicago

Wu, Hong Gyun, Si Yeol Song, Yeon Sil Kim, Young Taek Oh, Chang Geol Lee, Ki Chang Keum, Yong Chan Ahn, and Sang-wook Lee. 2009. “Therapeutic Effect of Recombinant Human Epidermal Growth Factor (RhEGF) on Mucositis in Patients Undergoing Radiotherapy, with or without Chemotherapy, for Head and Neck Cancer: A Double-Blind Placebo-Controlled Prospective Phase 2 Multi-Institutional Clinical Trial.” Cancer 115 (16): 3699–3708. doi:10.1002/cncr.24414.